Michelle Carr, Author at BioTuesdays

Developments

Perimeter’s B-Series OCT with ImgAssist AI demonstrates super-superiority compared to standard-of-care in breast cancer surgery pivotal clinical trial

Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) announced positive topline results from the pivotal study designed to support its planned FDA PMA submission for approval to market its next-generation Perimeter B...

November 20, 2024

Executive Moves

Opthea names Kathy Connell to BOD

Opthea (ASX/NASDAQ:OPT) announced the appointment of Kathy Connell to its board of directors as a non-executive director. Ms. Connell brings extensive business development expertise across pharmaceutical, vaccine...

November 15, 2024

Developments

BioRestorative Therapies preliminary BRTX-100 Phase 2 data for cLDD bolsters confidence in trial hitting primary and secondary endpoints

BioRestorative Therapies (NASDAQ:BRTX) announced new preliminary 26–52 week blinded data from the first 10 patients with chronic lumbar disc disease (cLDD) enrolled in the ongoing Phase 2 clinical trial of BRTX-100...

November 13, 2024

Developments

Lipella’s liposomal delivery platform granted patent by USPTO

Lipella Pharmaceuticals (NASDAQ:LIPO) announced that the U.S. Patent and Trademark Office (USPTO), has issued a patent for its proprietary liposomal delivery platform today. Lipella reports that the patent protects its...

November 12, 2024

Developments

Profound’s 2025 TULSA CMS reimbursement level leapfrogs all other prostate disease modalities

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that the U.S. Centers for Medicare and Medicaid Services has issued its final rule establishing, for the first time, a Category 1 CPT code for the Transurethral...

November 4, 2024

Developments

Lexicon signs exclusive licencing agreement with Viatris for sotagliflozin outside U.S. and Europe

Lexicon Pharmaceuticals (NASDAQ:LXRX) has announced that Viatris (NASDAQ:VTRS) obtained an exclusive license from Lexicon to commercialize sotagliflozin across all indications outside the U.S. and Europe, in exchange...

October 17, 2024

Markets

Capricor prices common stock offering

Capricor Therapeutics (NASDAQ:CAPR) has priced a public offering of 4,412,000 common shares at a price of $17.00 per share. Capricor also granted underwriters a 30-day option to purchase up to an additional 661,800...

October 17, 2024

Executive Moves

Tom Tamberrino joins Profound as new CCO ahead of TULSA reimbursement going into effect at the start of 2025

Profound Medical (NASDAQ:PROF; TSX:PRN) announced the appointment of Tom Tamberrino as chief commercial officer (CCO). Abbey Goodman, the current CCO, will now lead strategic partnerships and continue to report to CEO...

October 17, 2024

Developments

Corbus reports enrollment completion of dose escalation stage of Phase 1 trial

Corbus Pharmaceuticals (NASDAQ:CRBP) has announced the completion of enrollment for the dose-escalation portion of its bridging Phase 1 clinical trial of CRB-701 (SYS6002) in patients with advanced solid tumors...

October 16, 2024

Executive Moves

Murat Omur joins Ladenburg Thalmann as managing director in healthcare IB

Ladenburg Thalmann has announced the appointment of Murat Omur as managing director in the healthcare investment banking division. With 17 years of investment banking experience in healthcare and the M&A sector, Mr...

October 15, 2024

Author - Michelle Carr

Perimeter’s B-Series OCT with ImgAssist AI demonstrates super-superiority compared to standard-of-care in breast cancer surgery pivotal clinical trial

Opthea names Kathy Connell to BOD

BioRestorative Therapies preliminary BRTX-100 Phase 2 data for cLDD bolsters confidence in trial hitting primary and secondary endpoints

Lipella’s liposomal delivery platform granted patent by USPTO

Profound’s 2025 TULSA CMS reimbursement level leapfrogs all other prostate disease modalities

Lexicon signs exclusive licencing agreement with Viatris for sotagliflozin outside U.S. and Europe

Capricor prices common stock offering

Tom Tamberrino joins Profound as new CCO ahead of TULSA reimbursement going into effect at the start of 2025

Corbus reports enrollment completion of dose escalation stage of Phase 1 trial

Murat Omur joins Ladenburg Thalmann as managing director in healthcare IB

Subscribe